КЛИНИЧЕСКАЯ И СТАТИСТИЧЕСКАЯ ЗНАЧИМОСТЬ РЕЗУЛЬТАТОВ КЛИНИЧЕСКИХ ИСПЫТАНИЙ КАК КРИТЕРИИ ВЫБОРА БЕТА-АДРЕНОБЛОКАТОРА ДЛЯ ЛЕЧЕНИЯ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ


Цитировать

Полный текст

Аннотация

Обсуждается вопрос о критериях оценки клинической и статистической значимости результатов рандомизированных клинических испытаний лекарственных средств, в частности, бета-адреноблокаторов (БАБ), позволяющих вносить соответствующие поправки в клинические рекомендации по их применению. При выборе БАБ для лечения сердечно-сосудистых заболеваний или профилактики развития их осложнений следует ориентироваться, прежде всего, на доказательную базу применения конкретного препарата. В ходе выполнения исследований по оценке эффективности БАБ должно быть установлено не только статистически значимое снижение риска развития соответствующих осложнений заболеваний сердечно-сосудистой системы, но и достаточно высокая клиническая значимость полученных результатов

Об авторах

S Gilyarevsky

I Kuzmina

Сергей Руджерович Гиляревский

НИИ скорой помощи им. Н.В. Склифосовского, Москва

НИИ скорой помощи им. Н.В. Склифосовского, Москва

Ирина Михайловна Кузьмина

НИИ скорой помощи им. Н.В. Склифосовского, Москва

НИИ скорой помощи им. Н.В. Склифосовского, Москва

Список литературы

  1. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55.
  2. Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases. J Am Coll Cardiol 2009;54:585-94.
  3. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372;1223-30.
  4. Stiles S. FDA will argue against nebivolol approval for HF. Available at: www.theheart.org <http://www.theheart.org>.
  5. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. JACC 2009;53:81-90.
  6. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
  7. Kaul S, Diamond GA. Trial and Error. How to Avoid Commonly Encountered Limitations of Published Clinical Trials. J Am Coll Cardiol 2010;55:415-27.
  8. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426-35.
  9. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26:1115-40.
  10. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001;104:2996-3007.
  11. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6.
  12. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999;353:9-13.
  13. MERIT-HF Study group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
  14. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
  15. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002;360:1631-9.
  16. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358:439-444.
  17. Packer M. Pathophysiology of heart failure. Lancet 1992;340:88-95.
  18. Campbell DJ, Aggarwal A, Esler M, et al. Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001;358:1609-10.
  19. Teisman AC, van Veldhuisen DJ, Boomsma F, et al. Chronic beta-blocker treatment in patients with advanced heart failure: effects on neurohormones. Int J Cardiol 2000;73:7-14.
  20. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 1997;30:1589-97.
  21. Huirkuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.
  22. Lane RE, Cowie MR, Chow AW. Prediction and prevention of sudden cardiac death in heart failure. Heart 2005;91:674-80.
  23. Dobre D, van Veldhuisen DJ, Goulder MA, et al. Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. Cardiovasc Drugs Ther 2008;22:399-405.
  24. Poole-Wilson PA, Uretsky BF, Thygesen K, et al. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003;89:42-8.
  25. Simon T, Mary-Krause M, Funck-Brentano C, et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). Eur Heart J 2003;24:552-9.
  26. Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-8.
  27. McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784-94
  28. Cleland JGF, Coletta AP, Torabi A, et al. Clinical trials update from the European Society of Cardiology heart failure meeting: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF. J Heart Fail 2009;11:802-5.
  29. de Groote P, Isnard R, Assyag P, et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 2007;9:1205-11.
  30. de Groote P, Isnard R, Clerson P, et al. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. Eur J Heart Fail 2009;11:85-91.
  31. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341:1789-94.
  32. Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009;249:921-6.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2010

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах